Skip to main content

Table 2 Participant characteristics for treatment cohort

From: The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

Participant Age Sex MS Phenotype Duration of MS (years) EDSS at entry Clinical episode of optic neuritis Optic nerve affected Time elapsed since first clinical episode of optic neuritis (years)
1 44 Male SPMS 19 6 Yes Right 19
2 51 Male SPMS 26 6 Yes Both 26 (left); 9 (right)
3 40 Female SPMS 13 6.5 No Left* 6
4 48 Male SPMS 27 6 Yes Left 27
5 48 Male SPMS 12 6.5 Yes Right 11
6 52 Male SPMS 18 6 Yes Right 18 & 13
7 53 Female SPMS 5 6 Yes Left 6
8 51 Male SPMS 7 5.5 Yes Both 2 (left); 7 (right)
9 46 Female SPMS 11 6 Yes Both 5
10 51 Male SPMS 6 6.5 Yes Both 6
  1. SPMS = secondary progressive multiple sclerosis, EDSS = expanded Kurtzke disability status scale. * First episode of Uhthoff's phenomenon 6 years prior to recruitment.